Abstract
A 67-year-old man underwent total resection of the left lung because of adenocarcinoma, with no evidence of extra-thoracic spread of the cancer. On follow-up, metastatic bone disease was documented and chemotherapy (CMT) which included cisplatin, docetaxel, vinorelbine, and topotecan was administered. Six months after completion of CMT, a rise in total serum protein was noted. Bone marrow biopsy revealed the diagnosis of an IgG lambda myeloma. We report a case of a man with adenocarcinoma of the lung who presented multiple myeloma after completion of chemotherapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Felder B. Multiple myeloma and its treatment. Clin J Oncol Nurs. 2002;6(6):359–62.
Hayashi T, Hideshima T, Anderson KC. Novel therapies for multiple myeloma. Br J Haematol. 2003;120:10–7.
Ochiai N, Shimazaki C, Inaba T, et al. Effect of vinorelbine on the growth of human myeloma cell lines in vitro. Leuk Res. 2002;26(8):731–8.
Kraut EH, Ju R, Muller M. The use of topoisomerase I inhibitors in multiple myeloma. Semin Hematol. 1998;35(3 Suppl 4):32–8.
Bargetzi MJ, Passweg J, Baertschi E, et al. Mobilization of peripheral blood progenitor cells with vinorelbine and granulocyte colony-stimulating factor in multiple myeloma patients is reliable and cost effective. Bone Marrow Transplant. 2003;31(2):99–103.
Law IP, Blom J. Second malignancies in patients with multiple myeloma. Oncology. 1977;34:20–4.
Hideshima T, Chauhan D, Schlossman RL, et al. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic application. Oncogene. 2001;20:4519–27.
Fabris S, Todoerti K, Mosca L, et al. Molecular and transcriptional characterization of the novel 17p11.2-p12 amplicon in multiple myeloma. Genes Chromosomes Cancer. 2007;46(12):1109–18.
Coleman CN. Secondary neoplasms in patients treated for cancer: etiology and prospective. Radiat Res. 1982;92:188–200.
Zighelboim I, Babb S, Gao F, et al. Excess of early onset multiple myeloma in endometrial cancer probands and their relatives suggests common susceptibility. Gynecol Oncol. 2007;105:390–4.
Colla S, Tagliaferri S, Morandi F, et al. The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of pro-angiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angiogenesis. Blood. 2007;110(13):4464–75.
Schenkein DP. Preclinical data with bortezomib in lung cancer. Clin Lung Cancer. 2005;7(Suppl 2):S49–55.
Williams AR, Weiss WS, Koepsell TD, et al. Infectious and non infectious exposure in the etiology of light chain myeloma: a case control study. Cancer Res. 1989;49:4038–41.
Amadori D, Ronconi S. Secondary lung tumors in hematological patients. Semin Respir Crit Care Med. 2005;26(5):520–6.
Schöllkopf C, Rosendahl D, Rostgaard K, et al. Risk of second cancer after chronic lymphocytic leukemia. Int J Cancer. 2007;121(1):151–6.
Geffen DB, Cagnano E, Tokar M, et al. Ipsilateral breast carcinoma following treatment for primary breast lymphoma. Onkologie. 2007;30(3):134–6.
Maddocks-Christianson K, Slager SL, Zent CS, et al. Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia. Br J Haematol. 2007;139(3):398–404.
Author information
Authors and Affiliations
Corresponding author
Additional information
Department of Respiratory and Critical Care Medicine (KAA), Sotiria Chest Hospital—Institution in which the work was performed.
Rights and permissions
About this article
Cite this article
Marinopoulos, S., Skorda, L., Karatapanis, S. et al. Multiple myeloma emerging after chemotherapy for non-small-cell lung cancer. Med Oncol 25, 415–418 (2008). https://doi.org/10.1007/s12032-008-9056-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12032-008-9056-0